Andrea Pfeifer Biography and Net Worth

Co-Founder, Chief Executive Officer and Director of AC Immune

Prof. Andrea Pfeifer co-founded AC Immune SA in 2003, successfully leading it to an IPO in 2016, since when she has served as a Director on the Board. Under her leadership, multiple transformative partnerships have been established with leading pharmaceutical companies, yielding a potential value of up to CHF 3.3 billion plus additional royalties. Before founding the Company, she was the Head of Nestlé Research Centre in Lausanne, Switzerland where she played a major role in connecting science and business. Whilst at Nestlé she led the scientific development of a number of highly innovative, critically acclaimed products from laboratory to market, established the microbiome as a major cross-category product development platform and co-founded the Life Science focused Nestlé Venture Capital Fund. Prior to this she was a Visiting Fellow at the Human Carcinogenesis Branch of The National Institute of Health, Bethesda, USA. She currently serves as the Chair of Investment Fund BioMedInvest, Basel and AB2 Bio SA, Lausanne, and is a member of the Supervisory Board of Symrise AG, Holzminden, Germany. She is also a key member of the CEOi initiative on Alzheimer’s Disease and the Davos Alzheimer’s Collaborative (DAC). In 2021, she was awarded the first SEF.WomenAward for CEO of the Year by the Swiss Economic Forum. Prof. Pfeifer holds a Ph.D. in Toxicology (Cancer Research) from the University of Würzburg, Germany and is a registered Toxicologist and Pharmacist. She received her Habilitation from the University of Lausanne, Switzerland and is an Honorary Professor at the Ecole Polytechnique Fédérale de Lausanne (EPFL).

What is Andrea Pfeifer's net worth?: The estimated net worth of Andrea Pfeifer is at least $9.69 million as of May 15th, 2026. Dr. Pfeifer owns 3,820,288 shares of AC Immune stock worth more than $9,688,250 as of June 22nd. This net worth evaluation does not reflect any other investments that Dr. Pfeifer may own. Learn More about Andrea Pfeifer's net worth.
How do I contact Andrea Pfeifer?: The corporate mailing address for Dr. Pfeifer and other AC Immune executives is EPFL Innovation Park Building B, Lausanne V8, 1015. AC Immune can also be reached via phone at (121) 345-9121 and via email at [email protected]. Learn More on Andrea Pfeifer's contact information.
Has Andrea Pfeifer been buying or selling shares of AC Immune?: Within the last three months, Andrea Pfeifer has sold $27,900.00 of AC Immune stock. Most recently, Andrea Pfeifer sold 10,000 shares of the business's stock in a transaction on Friday, May 15th. The shares were sold at an average price of $2.79, for a transaction totalling $27,900.00. Following the completion of the sale, the chief executive officer now directly owns 3,820,288 shares of the company's stock, valued at $10,658,603.52. Learn More on Andrea Pfeifer's trading history.
Are insiders buying or selling shares of AC Immune?: During the last year, insiders at the sold shares 1 times. They sold a total of 10,000 shares worth more than $27,900.00. The most recent insider tranaction occured on May, 15th when CEO Andrea Pfeifer sold 10,000 shares worth more than $27,900.00. Insiders at AC Immune own 4.6% of the company. Learn More about insider trades at AC Immune.
Information on this page was last updated on 5/15/2026.

Andrea Pfeifer Insider Trading History at AC Immune

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/15/2026	Sell	10,000	$2.79	$27,900.00	3,820,288

Andrea Pfeifer Buying and Selling Activity at AC Immune

AC Immune Company Overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Today's Range

Now: $2.53

$2.44

$2.57

50 Day Range

MA: $2.76

$2.12

$3.40

2 Week Range

Now: $2.53

$1.65

$4.00

Volume

302,760 shs

Average Volume

307,857 shs

Market Capitalization

$256.97 million

P/E Ratio

N/A

Dividend Yield